EURONEXT-BRU$ARGX
Argenx Se · Q4 2026 earnings
Q4 2026 earnings · · Before market open · Investor relations
Briefing
ARGX Q4 2026 — extraction skipped
Argenx Se filed Form 6-K (accession 0001104659-26-045083) for Q4 2026, but headline financial numerics could not be extracted automatically: cached document missing (fetch error or PDF). The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.
- Form 6-K filed; press release body not parseable here.
- Reason: cached document missing (fetch error or PDF).
- Numerics rely on the Financial Datasets fallback.
Headline financials
Revenue & EPS history
Argenx · Revenue · Quarterly
$1.32B
Forward guidance
argenx highlighted continued expansion in 2026, including regulatory milestones, label expansions and pipeline advancement across multiple indications.
Tailwinds
- PDUFA target action date for seronegative gMG on May 10, 2026.
- Planned sBLA submission to expand VYVGART into ocular MG.
- Topline results for ADVANCE-NEXT in primary ITP expected in Q4 2026.
- Progression of multiple Phase 3 and earlier-stage pipeline programs.
- VYVGART SC autoinjector expected to launch in 2027.
Headwinds
- Forward-looking statements subject to clinical and regulatory risks.
- Dependence on continued VYVGART commercial performance.
- Ongoing R&D investments increasing operating expenses.
- Regulatory approval timing uncertainty.
- Exposure to global economic and regulatory factors.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2026
+0.3%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.8%
Avg return
30 days after
56%
18 / 32 earnings
Positive
+11.2%
Q4 2017
Best reaction
-9.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.7% | -8.1% | -19.0% | |
| Q1 2025 | -9.1% | -12.9% | -5.9% | |
| Q4 2024 | +0.3% | -0.3% | -5.4% | |
| Q3 2024 | +8.0% | +9.2% | +11.8% | |
| Q2 2024 | +6.5% | +9.7% | +11.3% | |
| Q1 2024 | -3.0% | -7.8% | -2.7% | |
| Q3 2023 | +6.6% | +7.7% | -2.9% | |
| Q2 2023 | -1.1% | -3.3% | -2.7% | |
| Q1 2023 | +3.0% | +2.4% | +0.9% | |
| Q4 2022 | -5.9% | -8.1% | +1.0% | |
| Q3 2022 | +1.4% | -1.1% | -2.6% | |
| Q2 2022 | +1.8% | -0.0% | +7.3% | |
| Q1 2022 | +8.0% | +2.2% | +8.0% | |
| Q4 2021 | -8.7% | -9.5% | +11.7% | |
| Q3 2021 | +8.0% | +14.8% | -1.2% | |
| Q2 2021 | -1.0% | +1.3% | +9.5% | |
| Q1 2021 | +6.3% | +0.8% | +20.4% | |
| Q4 2020 | -8.4% | -0.3% | -10.7% | |
| Q3 2020 | -2.5% | +0.8% | +4.9% | |
| Q2 2020 | -7.8% | -7.2% | -8.2% | |
| Q1 2020 | +5.7% | +10.0% | +45.0% | |
| Q4 2019 | -6.1% | -2.1% | -13.2% | |
| Q3 2019 | +0.4% | +4.9% | +24.8% | |
| Q2 2019 | +1.5% | -4.4% | -6.4% | |
| Q1 2019 | -3.2% | -6.2% | -3.0% | |
| Q4 2018 | +0.4% | -2.3% | -6.9% | |
| Q3 2018 | -5.0% | -3.9% | +17.2% | |
| Q2 2018 | -1.2% | -0.9% | +1.8% | |
| Q1 2018 | +2.6% | +3.5% | +13.2% | |
| Q4 2017 | +11.2% | +7.7% | +5.0% | |
| Q3 2017 | +1.1% | +0.7% | +13.4% | |
| Q2 2017 | -0.6% | -0.6% | +4.2% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro